No annual revenue total was found in LianBio's SEC filings.
LianBio (LIANY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$101.0 million. As of Sep 30, 2023 it held $252.2 million in cash and investments and $2.8 million in total debt.
Revenue
—
Net income (TTM)
$-87.98M
+22.3% vs year-ago TTM
Operating cash flow (TTM)
$-83.53M
+15.5% vs year-ago TTM
Free cash flow (TTM)
$-83.99M
+17.0% vs year-ago TTM
EPS (TTM)
$-0.82
Dividend per share
None
Shares outstanding
107.16M
-0.1% vs prior year
Net cash
$249.38M
as of Sep 30, 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIANY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1831283
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|
| Operating income | -$125.4M | -$195.6M |
| Net income | -$110.3M | -$196.3M |
| Diluted EPS | -$1.02 | -$5.71 |
| Operating cash flow | -$99.2M | -$164.0M |
| Free cash flow | -$101.0M | -$164.9M |
| Total assets | $320.0M | $426.3M |
| Total liabilities | $26.3M | $39.0M |
| Stockholders' equity | $259.9M | $353.6M |
| Cash and investments | $302.4M | $383.2M |
| Total debt | $4.3M | $4.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Listing notice, Regulation FD disclosure, Other events
|
Feb 13, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Dec 26, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 20, 2023 | Dec 19, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 19, 2023 | Dec 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 6, 2023 | Dec 6, 2023 |
| 8-K |
Current report
Other events
|
Dec 1, 2023 | Nov 30, 2023 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.